2020 Guide to Patient Support Services

Amgen

Amgen Assist 360 provides several support services for insured, ­uninsured, and underinsured patients who encounter financial hardships and cannot afford the Amgen medications they are prescribed, including Amgen FIRST STEP and the Amgen Safety Net Foundation.

The complete list of cancer drugs from Amgen, including Aranesp (darbepoetin alfa), Blincyto (blinatumomab), Epogen (epoetin alfa), Imlygic (talimogene laherparepvec), Kanjinti (trastuzumab-anns), Kyprolis (carfilzomib), Mvasi (beva­cizumab-awwb), Neulasta (pegfilgrastim), Neupogen (filgrastim), Nplate (romiplostim), Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab), is provided in the Table.

Because individual copay foundations have their own eligibility criteria and application process, Amgen urges patients to contact each foundation directly for eligibility information.

AMGEN SUPPORT PROGRAMS

Amgen FIRST STEP

Amgen FIRST STEP helps qualified, commercially insured patients cover their deductible, coinsurance, or copay costs.

Under this program, patients who are prescribed an Amgen-covered medication will:

  • Have $0 out-of-pocket costs for the first dose
  • For subsequent doses, Amgen pays the patient’s combined out-of-pocket cost in excess of $5 per dose; and for Prolia out-of-pocket cost of more than $25; with a maximum benefit of $1500 ­annually
  • Maximum program benefits are drug-specific and range from $10,000 to $20,000 per patient per calendar year.

This program has no income eligibility requirements.

Amgen Safety Net Foundation

The Amgen Safety Net Foundation is a nonprofit assistance program supported by Amgen that provides qualifying uninsured or underinsured patients with Amgen drugs at no cost.

For patients with government ­insurance, Medicare, or Medicaid, Amgen Assist 360 also helps by providing referrals to independent nonprofit foundations that can help with paying for medications.

ELIGIBILITY

Amgen FIRST STEP

To qualify for the Amgen FIRST STEP program, a patient:

  • Must be prescribed an Amgen drug covered by the program
  • Must have private commercial health insurance coverage for the prescribed medication
  • Must not have government insurance (eg, Medicare, Medicaid)
  • Can have any income level
  • Must not be a resident of a state where coupons or copay programs are not valid.

Amgen Safety Net Foundation

To qualify for this program, pa­tients must:

  • Have lived in the United States or its territories for ≥6 months
  • Satisfy income eligibility requirements
  • Have no insurance, or their insurance plan excludes the Amgen medicine.

In certain cases, patients who are underinsured or who have Medicare Part D coverage may qualify to receive support.

APPLICATION & ENROLLMENT

Amgen Assist 360

When patients enroll in Amgen Assist 360, Amgen Nurse Ambassador is a single point of contact who can help patients find the resources that are most important to them. Whatever type of insurance you have, even if you have none, your Amgen Nurse Ambassador can help you understand how your Amgen medicine may be covered, and refer you to programs that may be able to help you afford it.

Your Amgen Nurse Ambassador can refer you to nonprofit organizations that may provide you with community resources. Patients who are prescribed Blincyto, Imlygic, Kyprolis, or Nplate can enroll in Amgen Nurse Ambassador by completing the enrollment form.

Amgen FIRST STEP

Eligible patients must be enrolled in the individual drug-­specific program for the Amgen medication they have been prescribed.

Out-of-pocket costs for Amgen FIRST STEP must be associated with medications purchased and administered at a participating clinic or institution; the clinic or institution must be enrolled in the program before its patients can participate.

The healthcare provider submits the necessary materials and informs the patient if he or she qualified for the program. The Amgen FIRST STEP program MasterCard can be used with mail-order and specialty pharmacies.

The program is valid for the enrolled patient’s entire course of treatment and does not require re-enrollment. However, for continued eligibility, the patient’s explanation of benefits must be submitted within 45 days of each swipe of the Amgen FIRST STEP copay coupon. If the explanation of benefits is delayed, contact the Help Desk (888-657-8371) for an extension.

Amgen Safety Net Foundation

To enroll in the Amgen Safety Net Foundation, patients must submit the Patient Application Form and any supporting materials. The patient and the provider are notified on the approval of the application and what costs will be covered.

The Amgen Safety Net Foundation requires reapplication to the program each year. The foundation has 3 models of enrollment.

Prescription enrollment
This model applies to Amgen drugs that require a prescription and delivery of medication in advance of its administration. For the applicable Amgen drug, this model requires the submission of a drug’s prescription form completed by the prescriber or an original prescription to the foundation.

Replacement enrollment
This model applies to replacement drugs for physician-administered medications. In this model, the Amgen drug is first administered to qualifying foundation patients from the physician’s existing commercial stock, and then the replacement for this drug is ordered from the foundation. These drugs must be administered in an outpatient setting to be eligible for replacement.

On Demand enrollment
This model applies to certain physician-administered Amgen drugs that require delivery of the medication in advance of its administration. In this model, an On Demand Product Request Form is completed by the provider after the patient is enrolled in the foundation.

RECEIVING AMGEN MEDICATIONS

Amgen Safety Net Foundation

The Amgen Safety Net Foundation has 3 ways of providing medications based on the enrollment model. Check online at AmgenSafetyNetFoundation.com for drug-­specific information.

Prescription enrollment
The foundation ships prescription drugs directly to the patient for all drugs included in this model, except for Prolia, which is shipped directly to the provider.

Replacement enrollment
These drugs are sent directly to the prescriber.

On Demand enrollment
On Demand drugs are shipped directly to the provider in advance of administration.

TABLE AMGEN ONCOLOGY/SUPPORTIVE CARE DRUGS

Drugs
Indications
Patient support programs

Drug
Aranesp (darbepoetin alfa)
Indications
Chemotherapy-induced anemia
Patient support program

Drug
Blincyto (blinatumomab)
Indications
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia; B-cell precursor acute lymphoblastic leukemia in first or second complete remission, with minimal residual disease
Patient support programs

Drug
Epogen (epoetin alfa)
Indications
Chemotherapy-induced anemia
Patient support program

Drug
Imlygic (talimogene laherparepvec)
Indications
Melanoma with unresectable cutaneous, subcutaneous, or nodal lesions
Patient support programs

Drug
Kanjinti (trastuzumab-anns)
Indications
Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Patient support programs

Drug
Kyprolis (carfilzomib)
Indications
Relapsed or refractory multiple myeloma, in combination with dexamethasone or with lenalidomide and dexamethasone
Patient support programs

Drug
Mvasi (bevacizumab-awwb)
Indications
Treatment of recurrent glioblastoma; treatment of persistent, recurrent, or metastatic cervical cancer, in combination with chemotherapy; treatment of metastatic colorectal cancer, in combination with chemotherapy or after disease progression with a bevacizumab-containing regimen; treatment of unresectable, locally advanced, recurrent, or metastatic nonsquamous NSCLC, in combination with carboplatin and paclitaxel; treatment of metastatic renal-cell carcinoma, in combination with interferon-alfa
Patient support programs

Drug
Neulasta (pegfilgrastim)
Indications
Growth factor support for patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs
Patient support programs

Drug
Neupogen (filgrastim)
Indications
Growth factor support for patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs
Patient support programs

Drug
Nplate (romiplostim)
Indications
Thrombocytopenia in patients with chronic immune thrombocytopenia
Patient support programs

Drug
Prolia (denosumab)
Indications
Increase bone mass (1) in men with prostate cancer receiving androgen-deprivation therapy, or (2) in women with breast cancer receiving adjuvant aromatase inhibitor therapy
Patient support programs

Drug
Vectibix (panitumumab)
Indications
Metastatic colorectal cancer with wild-type KRAS
Patient support programs

Drug
Xgeva (denosumab)
Indications
Bone metastasis from solid tumors; unresectable giant-cell tumor of the bone; hypercalcemia of malignancy refractory to bisphosphonate therapy
Patient support programs

NSCLC indicates non–small-cell lung cancer.

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: